{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "375f6cb7",
   "metadata": {},
   "source": [
    "# Data 277B Spring 2025 Project"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "feb5c42b",
   "metadata": {},
   "source": [
    "## 1. Load Data and Begin Data Exploration"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b959caa2",
   "metadata": {},
   "source": [
    "### Harvard Data Set"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3146c8c5",
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "outputs": [],
   "source": [
    "This dataset measures 34 chemicals against 35 cell lines, each derived from malignant or non-malignant breast tumor. \n",
    "For each condition (i.e. cell line x chemical), the chemical is tested against the cell line starting at 10uM with a 9-step, 1:2 fold serial dilution \n",
    "for a total of 9 data points per condition. Cell counts were taken before and after 3 days of treatment.\n",
    "\n",
    "Features of main dataset: \n",
    "- \"Cell Name\" --> Cell line \n",
    "- \"Small Molecule Name\" --> 1 of 34 small molecules listed. \n",
    "- \"Small Mol concentration\" --> IC50 values \n",
    "- \"Primary target\" --> protein/gene that chemical inhibits\n",
    "- \"Pathway\" --> Categorical variable with the (6) categories: Cell cycle, Chemotherapy, MAPK/nRTK, Misc, PI3K/mTOR, RTK\n",
    "- \"Mean Normalized Growht Rate Inhibition Value\" --> Mean Normalized Growth Rate Inhibition (GR) Values were calculated according to the following formula: 2^[log2(x(c)/x0)/log2(xctrl/x0)]-1 where x(c) is the mean of the measured ‘Live’ cell counts after a given treatment, x0 is the mean of the ‘Live’ cell counts from the day 0 untreated plate grown in parallel until the time of treatment, and xctrl is the mean of the ‘Live’ cell counts of the DMSO-treated control wells for all technical replicates. \n",
    "- \"Increased Fraction Dead\" -->  Fraction Dead is caluclated by summing dead cells and dividing by dead+live cells. The Increased Fraction Dead was calculated by subtracting the mean fraction of dead cells in the DMSO-treated control wells from the mean fraction of dead cells in the wells from a given treatment across all technical replicates.\n",
    "\n",
    "Features of cell line dataset:\n",
    "\n",
    "Features of chemical dataset: "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a25089a6",
   "metadata": {},
   "source": [
    "### Duke Data Set"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "outputs": [],
   "source": [
    "Features: \n",
    "    Patient ID\n",
    "    MRI Technical Info\n",
    "        Days from Diagonsis to MRI\n",
    "        Manufacturer (GE MEDICAL SYSTEM = 0, MPTronic softmare = 1, SIEMENS = 2)\n",
    "        Manufacturer Model Name (Avanto = 0, Optima MR450W = 1, SIGNA EXCITE = 2, SIGNA HDx=3, Signa HDxt=4, Skyra=5, Trio=6, TrioTim=7)\n",
    "        Scan Options (FAST_GEMS\\SAT_GEMS\\ACC_GEMS\\PFP\\FS=0,FAST_GEMS\\SAT_GEMS\\MP_GEMS\\ACC_GEMS\\PFP\\FS=1,FAST_GEMS\\SAT_GEMS\\MP_GEMS\\PFP\\FS=2,FAST_GEMS\\SAT_GEMS\\PFP\\FS=3,FS=4,PFP\\FS=5,PFP\\SFS=6,SAT_GEMS\\PFP\\FS=7,SFS=8)\n",
    "        Field Strength in Tesla (1.494=0,1.5=1,2.8936=2,3=3)\n",
    "        Patient Position During MRI (Feet First Prone as FFP=0, Head First Prone as HFP=1)\n",
    "        Image Position of Patient\n",
    "        Contrast Agent (GADAVIST=0, MAGNEVIST=1, MMAGNEVIST=2, MULTIHANCE=3, Name of agent not stated(but ContrastBolusAgent tag was present)=4, ContrastBolusAgent Tag Absent = 5)\n",
    "        Contrast Bolus Volume (mL) (6=0, 7=1, 8=2, 9=3, 10=4, 11=5, 11.88=6, 12=7, 13=8, 13.6=9, 14=10, 14.5=11, 15=12, 16=13, 17=14, 18=15, 19=16, 20=17, 25=18)\n",
    "        TR (Repetition Time)\n",
    "        TE (Echo Time)\n",
    "        Acquisition Matrix (320 X 320=0, 340 X 340=1, 350 X 350=2, 360 X 360=3, 384 X 360=4, 384 X 384=5, 448 X 251=6, 448 X 381=7, 448 X 430=8, 448 X 448=9, 512 X 358=10)\n",
    "        Slice Thickness (0.9=0, 0.95=1, 1=2, 1.04=3, 1.06=4, 1.1=5, 1.12=6, 1.15=7, 1.2=8, 1.23=9, 1.24=10, 1.25=11, 1.3=12, 1.4=13, 1.45=14, 1.5=15, 1.6=16, 1.8=17, 2=18, 2.2=19, 2.5=20)\n",
    "        Rows (320=0, 448=1, 512=2)\n",
    "        Reconstruction Diameter (260=0, 270=1, 280=2, 290=3, 300=4, 305=5, 310=6, 320=7, 330=8, 340=9, 350=10, 360=11, 370=12, 380=13, 390=14, 400=15, 410=16, 420=17, 430=18, 480=19)\n",
    "        Flip Angle (7=0, 8=1, 10=2, 12=3)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a174a910",
   "metadata": {},
   "source": [
    "### MetaBrick"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "outputs": [],
   "source": [
    "Features:\n",
    "Patient ID\n",
    "Age of Diagonisis\n",
    "Type of Breast Surgery\n",
    "    - Mastectomy\n",
    "    - Breast Convserving\n",
    "    - Mastectomy\n",
    "    - Null\n",
    "\n",
    "Cancer Type\n",
    "    - Breast Cancer\n",
    "\n",
    "Cancer Type Detailed\n",
    "    - Breast Invasive Ductal Carcinoma\n",
    "    - Breast Invasive Lobular Carcinoma\n",
    "    - Breast Mixed Ductal and Lobular Carcinoma\n",
    "    - Breast Angiosarcoma\n",
    "    - Invasive Breast Carcinoma\n",
    "    *Needs cleaning, some cancer details have errors\n",
    "\n",
    "Cellularity\n",
    "    - High, Moderate or Low\n",
    "\n",
    "Chemotheropy\n",
    "    - Yes or No\n",
    "\n",
    "Radio therapy\n",
    "    - Yes or No\n",
    "\n",
    "Pam50 + Claudin-low subtype\n",
    "    - claudin-low\n",
    "    - Lum A\n",
    "    - Lum B\n",
    "    - Normal\n",
    "    - Basal\n",
    "    - Her 2\n",
    "\n",
    "Cohort\n",
    "    - 1 - 9\n",
    "\n",
    "ER status measured by IHC\n",
    "\n",
    "ER Status\n",
    "\n",
    "Neoplasm Histologic Grade\n",
    "\n",
    "HER2 status measured by SNP6\n",
    "\n",
    "HER2 Status\n",
    "\n",
    "Tumor Other Histologic Subtype\t\n",
    "\n",
    "Hormone Therapy\t\n",
    "\n",
    "Inferred Menopausal State\t\n",
    "\n",
    "Integrative Cluster\t\n",
    "\n",
    "Primary Tumor Laterality\t\n",
    "\n",
    "Lymph nodes examined positive\n",
    "\n",
    "Mutation Count\t\n",
    "\n",
    "Nottingham prognostic index\t\n",
    "\n",
    "Oncotree Code\t\n",
    "\n",
    "Overall Survival (Months)\t\n",
    "\n",
    "Overall Survival Status\t\n",
    "\n",
    "PR Status\t\n",
    "\n",
    "Relapse Free Status (Months)\t\n",
    "\n",
    "Relapse Free Status\t\n",
    "\n",
    "Sex\t\n",
    "\n",
    "3-Gene classifier subtype\t\n",
    "\n",
    "Tumor Size\t\n",
    "\n",
    "Tumor Stage\t\n",
    "\n",
    "Patient's Vital Status\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8effea68",
   "metadata": {},
   "source": [
    "### SEER Breast Cancer Data Set"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "outputs": [],
   "source": [
    "AGE\n",
    "\n",
    "SEER*Stat Name: Age at diagnosis\n",
    "Field Description: This data item represents the age of the patient at diagnosis for this cancer. The code represents the patient’s actual age in years.\n",
    "\n",
    "\n",
    "\n",
    "RACE\n",
    "\n",
    "SEER*Stat Name: Race recode (White, Black, Other)\n",
    "Field Description: Race recode is based on the race variables and the American Indian/Native American IHS link variable. This recode should be used to link to the populations for white, black and other. It is independent of Hispanic ethnicity. For more information, see : http://seer.cancer.gov/seerstat/variables/seer/race_ethnicity.\n",
    "\n",
    "1\n",
    "\n",
    "White\n",
    "\n",
    "2\n",
    "\n",
    "Black\n",
    "\n",
    "3\n",
    "\n",
    "Other (American Indian/AK Native, Asian/Pacific Islander)\n",
    "\n",
    "4\n",
    "\n",
    "Other unspecified (1991+)\n",
    "\n",
    "5\n",
    "\n",
    "Unknown\n",
    "\n",
    " \n",
    "\n",
    " \n",
    "\n",
    "MARITAL STATUS\n",
    "\n",
    "SEER*Stat Name: Marital status at diagnosis\n",
    "\n",
    "Field Description: This data item identifies the patient’s marital status at the time of diagnosis for the reportable tumor.\n",
    "\n",
    "1\n",
    "\n",
    "Single (never married)\n",
    "\n",
    "2\n",
    "\n",
    "Married (including common law)\n",
    "\n",
    "3\n",
    "\n",
    "Separated\n",
    "\n",
    "4\n",
    "\n",
    "Divorced\n",
    "\n",
    "5\n",
    "\n",
    "Widowed\n",
    "\n",
    " \n",
    "\n",
    "T STAGE\n",
    "\n",
    "SEER*Stat Name: Breast Adjusted AJCC 6th T (1988+)\n",
    "Field Description: Created from merged EOD 3rd Edition and Collaborative Stage disease information. Currently only available for Breast schema. For more information see http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th.\n",
    "\n",
    "1\n",
    "\n",
    "T1\n",
    "\n",
    "2\n",
    "\n",
    "T2\n",
    "\n",
    "3\n",
    "\n",
    "T3\n",
    "\n",
    "4\n",
    "\n",
    "T4\n",
    "\n",
    " \n",
    "\n",
    "N STAGE\n",
    "\n",
    "SEER*Stat Name: Breast Adjusted AJCC 6th N (1988+)\n",
    "\n",
    "Field Description: Created from merged EOD 3rd Edition and Collaborative Stage disease information. Currently only available for Breast schema. For more information see http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th.\n",
    "\n",
    "1\n",
    "\n",
    "N1\n",
    "\n",
    "2\n",
    "\n",
    "N2\n",
    "\n",
    "3\n",
    "\n",
    "N3\n",
    "\n",
    " \n",
    "\n",
    "6TH STAGE\n",
    "\n",
    "SEER*Stat Name: Breast Adjusted AJCC 6th Stage (1988+)\n",
    "\n",
    "Field Description: Created from merged EOD 3rd Edition and Collaborative Stage disease information. Currently only available for Breast schema. For more information see http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th.\n",
    "\n",
    "1\n",
    "\n",
    "IIA\n",
    "\n",
    "2\n",
    "\n",
    "IIB\n",
    "\n",
    "3\n",
    "\n",
    "IIIA\n",
    "\n",
    "4\n",
    "\n",
    "IIIB\n",
    "\n",
    "5\n",
    "\n",
    "IIIC\n",
    "\n",
    " \n",
    "\n",
    "GRADE\n",
    "SEER*Stat Name: Grade\n",
    "Field Description: Grading and differentiation codes of 1-4, 9 are defined in ICD-O-2; 1992. Grade information may be incomplete for cases diagnosed before 1977. In the early 1980’s, additional codes specifying T-cell, B-cell, or null cell involvement in lymphomas and leukemias (histologies M9590-9940) were introduced by SEER. Because the reporting requirements and medical terminology have changed over time, care should be exercised when analyzing this information.\n",
    "\n",
    "1\n",
    "\n",
    "Grade I; grade i; grade 1; well differentiated; differentiated, NOS\n",
    "\n",
    "2\n",
    "\n",
    "Grade II; grade ii; grade 2; moderately differentiated; moderately differentiated; intermediate differentiation\n",
    "\n",
    "3\n",
    "\n",
    "Grade III; grade iii; grade 3; poorly differentiated; differentiated\n",
    "\n",
    "4\n",
    "\n",
    "Grade IV; grade iv; grade 4; undifferentiated; anaplastic\n",
    "\n",
    " \n",
    "\n",
    "A STAGE\n",
    "\n",
    "SEER*Stat Name: SEER historic stage A\n",
    "\n",
    "Field Description: Derived from Collaborative Stage (CS) for 2004+ and Extent of Disease (EOD) from 1973-2003. It is a simplified version of stage: in situ, localized, regional, distant, & unknown. Over time several different EOD schemes have been used. Thus caution should be used when doing trend analysis. For more information including sites and years for which it isn't calculated, see http://seer.cancer.gov/seerstat/variables/seer/lrd-stage.\n",
    "\n",
    "1\n",
    "\n",
    "Regional — A neoplasm that has extended 1) beyond the limits of the organ of origin\n",
    "directly into surrounding organs or tissues; 2) into regional lymph nodes by way of the\n",
    "lymphatic system; or 3) by a combination of extension and regional lymph nodes.\n",
    "\n",
    "2\n",
    "\n",
    "Distant — A neoplasm that has spread to parts of the body remote from the primary\n",
    "tumor either by direct extension or by discontinuous metastasis (e.g., implantation or\n",
    "seeding) to distant organs, issues, or via the lymphatic system to distant lymph nodes.\n",
    "\n",
    " \n",
    "\n",
    "TUMOR SIZE\n",
    "\n",
    "Code Description\n",
    "000 No mass/tumor found\n",
    "001 1 mm or described as less than 1 mm (0.1 cm or less than 0.1 cm)\n",
    "002-988 Exact size in millimeters (2 mm-988 mm) (0.2 cm to 98.8 cm)\n",
    "989 989 millimeters or larger (98.9 cm or larger)\n",
    "990 Microscopic focus or foci only and no size of focus is given\n",
    "998 Alternate descriptions of tumor size for specific sites:\n",
    "Familial/multiple polyposis:\n",
    "-Rectosigmoid and rectum (C19.9, C20.9)\n",
    "-Colon (C18.0, C18.2-C18.9)\n",
    "If no size is documented:\n",
    "Circumferential:\n",
    "-Esophagus (C15.0-C15.5, C15.8, C15.9)\n",
    "Diffuse; widespread: 3/4s or more; linitis plastica:\n",
    "-Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8, C16.9)\n",
    "Diffuse, entire lung or NOS:\n",
    "-Lung and main stem bronchus (C34.0-C34.3, C34.8, C34.9)\n",
    "Diffuse:\n",
    "-Breast (C50.0-C50.6, C50.8, C50.9)\n",
    "999 Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed;\n",
    "No excisional biopsy or tumor resection done; The only measurement(s) describes pieces or\n",
    "chips; Not applicable\n",
    "\n",
    "SEER*Stat Name: CS tumor size (2004+)\n",
    "\n",
    "Field Description: Information on tumor size. Available for 2004+. Earlier cases may be converted and new codes added which weren't available for use prior to the current version of CS. Each indicates exact size in millimeters. For more information, see http://seer.cancer.gov/seerstat/variables/seer/ajcc-stage.\n",
    "\n",
    "Exception to rounding rules for BREAST primaries: Round tumor sizes greater than 1.0\n",
    "mm and up to 2.4 mm to 2 mm (002). The purpose of this exception is so that the size\n",
    "recorded in the Tumor Size Summary data item will derive the correct AJCC TNM\n",
    "Primary Tumor (T) category for breast primaries. Do not apply this instruction to any\n",
    "other site.\n",
    " \n",
    "\n",
    "ESTROGEN STATUS\n",
    "\n",
    "SEER*Stat Name: ER Status Recode Breast Cancer (1990+)\n",
    "\n",
    "Field Description: Created by combining information from Tumor marker 1 (1990-2003) (NAACCR Item #=1150), with information from CS site-specific factor 1 (2004+) (NAACCR Item #=2880). This field is blank for non-breast cases and cases diagnosed before 1990.\n",
    "\n",
    "1\n",
    "\n",
    "Positive\n",
    "\n",
    "2\n",
    "\n",
    "Negative\n",
    "\n",
    " \n",
    "\n",
    "PROGESTERONE STATUS\n",
    "\n",
    "SEER*Stat Name: PR Status Recode Breast Cancer (1990+)\n",
    "\n",
    "Field Description: Created by combining information from Tumor marker 2 (1990-2003) (NAACCR Item #=1150), with information from CS site-specific factor 2 (2004+) (NAACCR Item #=2880). This field is blank for non-breast cases and cases diagnosed before 1990.\n",
    "\n",
    "1\n",
    "\n",
    "Positive\n",
    "\n",
    "2\n",
    "\n",
    "Negative\n",
    "\n",
    " \n",
    "\n",
    "REGIONAL NODES EXAMINED\n",
    "\n",
    "SEER*Stat Name: Regional nodes examined (1988+)\n",
    "\n",
    "Field Description: Records the total number of regional lymph nodes that were removed and examined by the pathologist.\n",
    "\n",
    " \n",
    "\n",
    "REGIONAL NODES POSITIVE\n",
    "\n",
    "SEER*Stat Name: Regional nodes positive (1988+)\n",
    "\n",
    "Field Description: Records the exact number of regional lymph nodes examined by the pathologist that were found to contain metastases.\n",
    "\n",
    "SURVIVAL MONTHS\n",
    "\n",
    "SEER*Stat Name: Survival Months\n",
    "\n",
    "Field Description: Created using complete dates, including days, therefore may differ from survival time calculated from year and month only. For more information, see http://seer.cancer.gov/survivaltime.\n",
    "\n",
    " \n",
    "\n",
    "STATUS\n",
    "\n",
    "SEER*Stat Name: Vital status recode (study cutoff used)\n",
    "Field Description: Any patient that dies after the follow-up cut-off date is recoded to alive as of the cut-off date.\n",
    "\n",
    "1\n",
    "\n",
    "Alive\n",
    "\n",
    "2\n",
    "\n",
    "Dead\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "language_info": {
   "name": "python"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
